Viddler

pffoundation

pffoundation

PFF Hill Day 2024 Training PFF Hill Day 2024 Training
Hill Day Training 2022_v3 Hill Day Training 2022_v3
Virtual Support Group Zoom Basics Training Virtual Support Group Zoom Basics Training
Life with PF - Gary and Marianne Life with PF - Gary and Marianne
Hill Day 2020 Prep Teleconference Hill Day 2020 Prep Teleconference
2019-12-20 14.39 Review Dark Matter Platform 2019-12-20 14.39 Review Dark Matter Platform
AskADoc_June2019 AskADoc_June2019
Support Group Advocacy Training Support Group Advocacy Training
Advance Directives_April2019 Advance Directives_April2019
PF and Mental Health_Feb2019 PF and Mental Health_Feb2019
Exposure-RelatedPF_013019 Exposure-RelatedPF_013019
CTD-ILD_Dec 2018 CTD-ILD_Dec 2018
The Diagnostic Process for PF_Oct 2018 The Diagnostic Process for PF_Oct 2018
FDA's Drug Approval Process_September2018 FDA's Drug Approval Process_September2018
PF Myths Debunked_August2018 PF Myths Debunked_August2018
advocacyAug18 advocacyAug18
researchupdate2018 researchupdate2018
Non-Genetic Causes of PF_April2018 Non-Genetic Causes of PF_April2018
Lung Transplantation_March 2018 Lung Transplantation_March 2018
AskADoc_January2018 AskADoc_January2018
Patient Assistance Programs-IPFTherapies_December 2017 Patient Assistance Programs-IPFTherapies_December 2017
Summit Prep Teleconference_2017 Summit Prep Teleconference_2017
PFF Daughters Teleconference_10.27.17 PFF Daughters Teleconference_10.27.17
PFF Disease Education Webinar_Clinical Trials Overview September 2017 PFF Disease Education Webinar_Clinical Trials Overview September 2017
PFF Disease Education Webinar_Nutrition and ILD August 2017 PFF Disease Education Webinar_Nutrition and ILD August 2017
August 2017 SGLN Teleconference August 2017 SGLN Teleconference
PFF Ambassador_August 2017 Teleconference PFF Ambassador_August 2017 Teleconference
PFF Ambassador Teleconference July 2017 PFF Ambassador Teleconference July 2017
PFF Disease Education Webinar_Familial ILD and Genetics_July 2017 PFF Disease Education Webinar_Familial ILD and Genetics_July 2017
Ask a Doc Webinar_June2017 Ask a Doc Webinar_June2017
PFF Ambassador Teleconference_6.14.17 PFF Ambassador Teleconference_6.14.17
SGLN Teleconference_5.8.17 SGLN Teleconference_5.8.17
PFF Daughters Quarterly Tele_4.28.17 PFF Daughters Quarterly Tele_4.28.17
PFF Hill Day 2017 Prep Tele PFF Hill Day 2017 Prep Tele
Caregiving Webinar April 2017 Caregiving Webinar April 2017
PFF Ambassador Teleconference_3.15.17 PFF Ambassador Teleconference_3.15.17
Untitled Untitled
2017-02-21 14.10 PFF SGLN Teleconference 2017-02-21 14.10 PFF SGLN Teleconference
Hypersensitivity Pneumonitis_2.15.17 Hypersensitivity Pneumonitis_2.15.17
PFF Ambassador Teleconference_Jan17 PFF Ambassador Teleconference_Jan17
PFF Daughters Quarterly Teleconference_1.28.17 PFF Daughters Quarterly Teleconference_1.28.17
Anti-Inflammatory & Immunosuppressive Medications Anti-Inflammatory & Immunosuppressive Medications
Jordan Howard Ad in Times Square Jordan Howard Ad in Times Square
December Teleconference December Teleconference
SGLN Teleconference December 2016 SGLN Teleconference December 2016
PFF Ambassador Orientation_11.3.16 PFF Ambassador Orientation_11.3.16
Annual Vol Mtg_11.2.16 Annual Vol Mtg_11.2.16
October Teleconference October Teleconference
What is PF? Webinar-Arabic_09.7.16 What is PF? Webinar-Arabic_09.7.16
What Is PF? Webinar-Vietnamese_9.7.16 What Is PF? Webinar-Vietnamese_9.7.16
What Is PF? Webinar-Urdu_9.7.16 What Is PF? Webinar-Urdu_9.7.16
What Is PF? Webinar-Spanish_9.7.16 What Is PF? Webinar-Spanish_9.7.16
What Is PF? Webinar-Russian_9.7.16 What Is PF? Webinar-Russian_9.7.16
What is PF Webinar-Mandarin_9.7.16 What is PF Webinar-Mandarin_9.7.16
What Is PF? Webinar-Hindi_9.7.16 What Is PF? Webinar-Hindi_9.7.16
What Is PF? Webinar-English_9.7.16 What Is PF? Webinar-English_9.7.16
What Is PF? -Polish_9.7.16 What Is PF? -Polish_9.7.16
PFProgression Webinar_10.12.16 PFProgression Webinar_10.12.16
SGLN Teleconference August 2016 SGLN Teleconference August 2016
PFF Ambassador Teleconference_8.10.16 PFF Ambassador Teleconference_8.10.16
IPF PSA 60-Second FINAL IPF PSA 60-Second FINAL
PFF Daughters Steering Co Meeting_7.14.16 PFF Daughters Steering Co Meeting_7.14.16
ExercisePulmonaryRehab_7.13.2016 ExercisePulmonaryRehab_7.13.2016
PFF SGLN Teleconference_6.27.16 PFF SGLN Teleconference_6.27.16
Sirius XM Doctor Radio - Dr Glassberg 6-16-16 Sirius XM Doctor Radio - Dr Glassberg 6-16-16
Ambassador Teleconference_6.21.16 Ambassador Teleconference_6.21.16
Daughters Steering Co Teleconference_6.7.16 Daughters Steering Co Teleconference_6.7.16
Ambassador Teleconference_May 2016 Ambassador Teleconference_May 2016
Ambassador Teleconference_May 2016 Ambassador Teleconference_May 2016
OxygenEquipmentOverview_5.11.16 OxygenEquipmentOverview_5.11.16
7619791_USARADIO_AC 7619791_USARADIO_AC
7619791_ProjectHealth_AC 7619791_ProjectHealth_AC
UpdatePFResearchCCNRegistry_April2016FINAL UpdatePFResearchCCNRegistry_April2016FINAL
SGLN Teleconference_3.21.16 SGLN Teleconference_3.21.16
AskADocGERDSleepApnea31616 AskADocGERDSleepApnea31616
SGLN Training Webinar III SGLN Training Webinar III
Plenary Session and Panel Discussion: Leveraging the PFF Care Center Network | Leaders: Vincent Cottin, MD, PhD; Kevin R. Flaherty, MD, MS; Jesse Roman, MD Plenary Session and Panel Discussion: Leveraging the PFF Care Center Network | Leaders: Vincent Cottin, MD, PhD; Kevin R. Flaherty, MD, MS; Jesse Roman, MD
Julie_Halston_Broadway16_30sec Julie_Halston_Broadway16_30sec
Fibrosis as a Disease of Aging and Mitochondrial Dysfunction | Ana L. Mora, MD Fibrosis as a Disease of Aging and Mitochondrial Dysfunction | Ana L. Mora, MD
Integrating Biomarkers in Clinical Studies to Affect Patient Care | Fernando J. Martinez, MD, MS Integrating Biomarkers in Clinical Studies to Affect Patient Care | Fernando J. Martinez, MD, MS
Molecular and Cellular Biomarkers of Pulmonary Fibrosis | Naftali Kaminski, MD Molecular and Cellular Biomarkers of Pulmonary Fibrosis | Naftali Kaminski, MD
Mechanotransduction and the Role of Tissue Stiffness in Fibrosis | Mitchell Olman, MA, MD Mechanotransduction and the Role of Tissue Stiffness in Fibrosis | Mitchell Olman, MA, MD
Understanding PFTs_December 2015_2 Understanding PFTs_December 2015_2
Palliative and Advanced Care | Susan S. Jacobs, RN, MS Palliative and Advanced Care | Susan S. Jacobs, RN, MS
Question-and-Answer Period and Panel Discussion | Leader: Joseph A. Lasky, MD Question-and-Answer Period and Panel Discussion | Leader: Joseph A. Lasky, MD
Clinical Trials in the Era of Effective Therapies | Luca Richeldi, MD, PhD Clinical Trials in the Era of Effective Therapies | Luca Richeldi, MD, PhD
The Promise of Registries | Christopher J. Ryerson, MD The Promise of Registries | Christopher J. Ryerson, MD
PFF Patient Survey Results | Gregory P. Cosgrove, MD, FCCP PFF Patient Survey Results | Gregory P. Cosgrove, MD, FCCP
Patient Perspective: Living Well with Pulmonary Fibrosis | Charolette Saunders Patient Perspective: Living Well with Pulmonary Fibrosis | Charolette Saunders
patient_saturday_1145_Panel_C-Summit-2015 patient_saturday_1145_Panel_C-Summit-2015
Symptom Management | Maryl E. Kreider, MD, MSCE Symptom Management | Maryl E. Kreider, MD, MSCE
Lung Transplantation | Steven D. Nathan, MD, FCCP Lung Transplantation | Steven D. Nathan, MD, FCCP
patient_friday_1530_Courtney-Summit-2015 patient_friday_1530_Courtney-Summit-2015
Question-and-Answer Period and Panel Discussion | Leader: Marilyn K. Glassberg, MD Question-and-Answer Period and Panel Discussion | Leader: Marilyn K. Glassberg, MD
Managing Comorbidity | Vincent Cottin, MD, PhD Managing Comorbidity | Vincent Cottin, MD, PhD
Pulmonary Rehabilitation and Oxygen Therapy | Anne E. Holland, PhD Pulmonary Rehabilitation and Oxygen Therapy | Anne E. Holland, PhD
Pharmacologic Therapy | Charlene D. Fell, MD, MSc Pharmacologic Therapy | Charlene D. Fell, MD, MSc
Patient Perspective: Living Well with Pulmonary Fibrosis | Pete Mulliner Patient Perspective: Living Well with Pulmonary Fibrosis | Pete Mulliner
Question-and-Answer Period and Panel Discussion | Leader: Joao Alberto M. de Andrade, MD Question-and-Answer Period and Panel Discussion | Leader: Joao Alberto M. de Andrade, MD
Communicating Prognosis and Goals of Care | Sonye K. Danoff, MD, PhD Communicating Prognosis and Goals of Care | Sonye K. Danoff, MD, PhD
Diagnosing the Cause of Pulmonary Fibrosis | Kevin F. Gibson, MD Diagnosing the Cause of Pulmonary Fibrosis | Kevin F. Gibson, MD
What is Pulmonary Fibrosis and Why is it a Problem? | Joyce Lee, MD What is Pulmonary Fibrosis and Why is it a Problem? | Joyce Lee, MD
SGLN Training Webinar Session II_12.14.15 SGLN Training Webinar Session II_12.14.15
professional_Saturday_0830_Panel-Summit-2015 professional_Saturday_0830_Panel-Summit-2015
professional_Saturday_0830_Panel-Summit-2015 professional_Saturday_0830_Panel-Summit-2015
Plenary Session and Panel Discussion - The Future of Clinical Trials in Pulmonary Fibrosis | Leaders: David J. Lederer, MD, MS; Kevin K. Brown, MD Plenary Session and Panel Discussion - The Future of Clinical Trials in Pulmonary Fibrosis | Leaders: David J. Lederer, MD, MS; Kevin K. Brown, MD
Case Presentation I | Abigail R. Lara, MD Case Presentation I | Abigail R. Lara, MD
Case Presentation III | Andrew Youn, MD, FRCPC Case Presentation III | Andrew Youn, MD, FRCPC
Case Presentation II | Brett J. Ley, MD Case Presentation II | Brett J. Ley, MD
Presentation: How to Organize MDD in the Real World | Charlene D. Fell, MD, MSc Presentation: How to Organize MDD in the Real World | Charlene D. Fell, MD, MSc
Discussion Discussion
Palliative Care and Hospice: Losing or Retaking Control? | Kathleen O. Lindell, RN, PhD Palliative Care and Hospice: Losing or Retaking Control? | Kathleen O. Lindell, RN, PhD
Lung Transplantation: Nuts and Bolts or…This is Nuts, I am Going to Bolt | David J. Lederer, MD, MS Lung Transplantation: Nuts and Bolts or…This is Nuts, I am Going to Bolt | David J. Lederer, MD, MS
Towards an Improved Quality of Life: Starring Oxygen Therapy and Pulmonary Rehab | Anne E. Holland, PhD Towards an Improved Quality of Life: Starring Oxygen Therapy and Pulmonary Rehab | Anne E. Holland, PhD
5th Place: Renea Jablonski, SIRT3, the anti-aging major mitochondrial deacetylase, is important for preventing pulmonary fibrosis 5th Place: Renea Jablonski, SIRT3, the anti-aging major mitochondrial deacetylase, is important for preventing pulmonary fibrosis
Precision Medicine for IPF: Dream or Reality? | Imre Noth, MD Precision Medicine for IPF: Dream or Reality? | Imre Noth, MD
Novel Targets for the Future: What’s Promising? | Andrew M. Tager, MD Novel Targets for the Future: What’s Promising? | Andrew M. Tager, MD
Approved Drugs for IPF: Should They be Studied for Non-IPF Pulmonary Fibrosis? | Kevin K. Brown, MD Approved Drugs for IPF: Should They be Studied for Non-IPF Pulmonary Fibrosis? | Kevin K. Brown, MD
Clinical Topic I - Session Leader Introduction | Luca Richeldi, MD, PhD Clinical Topic I - Session Leader Introduction | Luca Richeldi, MD, PhD
4th Place: Louise Hecker, Impaired Myofibroblast Dedifferentiation Contributes to Non-Resolving Fibrosis in Aging 4th Place: Louise Hecker, Impaired Myofibroblast Dedifferentiation Contributes to Non-Resolving Fibrosis in Aging
Collaborative Networks as Tools for Improving Clinical Care | Pat Furlong Collaborative Networks as Tools for Improving Clinical Care | Pat Furlong
Panel Discussion Panel Discussion
Patient-Centered Research: PCORI and the Patient Voice | Sonye K. Danoff, MD, PhD Patient-Centered Research: PCORI and the Patient Voice | Sonye K. Danoff, MD, PhD
Measuring Function: Beyond the 6MWT | Amy L. Olson, MD Measuring Function: Beyond the 6MWT | Amy L. Olson, MD
How to Build a Patient-Reported Outcome (PRO) | Hilary Wilson, PhD How to Build a Patient-Reported Outcome (PRO) | Hilary Wilson, PhD
3rd Place: Rachel Scheraga, The mechanosensitive transient receptor potential vanilloid 4 (TRPV4) ion channel mediates the pro-resolution/anti-fibrotic macrophage response to endotoxin (LPS) 3rd Place: Rachel Scheraga, The mechanosensitive transient receptor potential vanilloid 4 (TRPV4) ion channel mediates the pro-resolution/anti-fibrotic macrophage response to endotoxin (LPS)
Discussion, Session Overview, and Close | Andrew M. Tager, MD Discussion, Session Overview, and Close | Andrew M. Tager, MD
The Role of Macrophages in Fibrosis | Michael R. Blackburn, PhD The Role of Macrophages in Fibrosis | Michael R. Blackburn, PhD
professional_friday_1355_Olman_G-Summit-2015 professional_friday_1355_Olman_G-Summit-2015
professional_friday_1335_Mora_G-Summit-2015 professional_friday_1335_Mora_G-Summit-2015
2nd Place: Justin Oldham, TOLLIP, MUC5B and the Response to N-acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis 2nd Place: Justin Oldham, TOLLIP, MUC5B and the Response to N-acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis
Question-and-Answer Period and Panel Discussion | Leaders: Ivan O. Rosas, MD; Christine Kim Garcia, MD, PhD Question-and-Answer Period and Panel Discussion | Leaders: Ivan O. Rosas, MD; Christine Kim Garcia, MD, PhD
professional_friday_1140_Martinez_G-Summit-2015 professional_friday_1140_Martinez_G-Summit-2015
professional_friday_1120_Kaminski_G-Summit-2015 professional_friday_1120_Kaminski_G-Summit-2015
Genetics of Pulmonary Fibrosis | Christine Kim Garcia, MD, PhD Genetics of Pulmonary Fibrosis | Christine Kim Garcia, MD, PhD
An Overview of Personalized Medicine for Pulmonary Fibrosis | Ivan O. Rosas, MD An Overview of Personalized Medicine for Pulmonary Fibrosis | Ivan O. Rosas, MD
1st Place: Robert Guzy, Fibroblast-specific FGF signaling in bleomycin-induced pulmonary fibrosis 1st Place: Robert Guzy, Fibroblast-specific FGF signaling in bleomycin-induced pulmonary fibrosis
The Future of Drug Development in Pulmonary Fibrosis — A Regulatory Perspective | Janet Woodcock, MD The Future of Drug Development in Pulmonary Fibrosis — A Regulatory Perspective | Janet Woodcock, MD
Familial PF Webinar_10.2015 Familial PF Webinar_10.2015
SGLN Training Webinar 1_October 2015 SGLN Training Webinar 1_October 2015
PF Advocacy Webinar_9.2.15 PF Advocacy Webinar_9.2.15
IMG_1308 (1) IMG_1308 (1)
IPF Treatment Guidelines_8.19.15 IPF Treatment Guidelines_8.19.15
AskADoc_6.10.15 AskADoc_6.10.15
Palliative Webinar_4.15.15 Palliative Webinar_4.15.15
Ask a Doc_3.18.15 Ask a Doc_3.18.15
Pulmonary Hypertension_3.11.15 Pulmonary Hypertension_3.11.15
Occupational and Environmental PF Webinar_2.4.15 Occupational and Environmental PF Webinar_2.4.15
Coping with PF_3 Coping with PF_3
Lung Transplantation_1.14.15 Lung Transplantation_1.14.15
Coping with PF Webinar_12.10.14 Coping with PF Webinar_12.10.14
Autoimmune-Related PF_11.12.14 Autoimmune-Related PF_11.12.14
Truth-Telling Webinar_10.22.14 Truth-Telling Webinar_10.22.14
Edited Leiberman Live Edited Leiberman Live
Drug Development Webinar_9.17.14 Drug Development Webinar_9.17.14
Supplemental Oxygen Webinar_9.3.14 Supplemental Oxygen Webinar_9.3.14
Caregiving 101 Caregiving 101
July 23 Webinar: Pulmonary Rehab, Support Groups & Q+A July 23 Webinar: Pulmonary Rehab, Support Groups & Q+A
July 23 Webinar: Intro & PFF Ambassador Story July 23 Webinar: Intro & PFF Ambassador Story
ipf consensus guidelines_7.16.14 ipf consensus guidelines_7.16.14
barcelona-talk-09-SP barcelona-talk-09-SP
barcelona-talk-09 barcelona-talk-09
barcelona-talk-08 barcelona-talk-08
barcelona-talk-07 barcelona-talk-07
barcelona-talk-06 barcelona-talk-06
barcelona-talk-06-SP barcelona-talk-06-SP
barcelona-talk-04 barcelona-talk-04
barcelona-talk-05 barcelona-talk-05
barcelona-talk-01 barcelona-talk-01
barcelona-talk-03 barcelona-talk-03
barcelona-talk-02 barcelona-talk-02
barcelona-talk-01-SP barcelona-talk-01-SP
Ask a Doc_5.28.14_final Ask a Doc_5.28.14_final
Webinar_5.14.14_final Webinar_5.14.14_final
Awareness-2012-Int-SP-08 Awareness-2012-Int-SP-08
Awareness-2012-Int-SP-06 Awareness-2012-Int-SP-06
Awareness-2012-Int-SP-07 Awareness-2012-Int-SP-07
Awareness-2012-Int-SP-03 Awareness-2012-Int-SP-03
Awareness-2012-Int-SP-02 Awareness-2012-Int-SP-02
Awareness-2012-Int-SP-09 Awareness-2012-Int-SP-09
Awareness-2012-Int-SP-04 Awareness-2012-Int-SP-04
Awareness-2012-Int-SP-01 Awareness-2012-Int-SP-01
Awareness-2012-Int-SP-05 Awareness-2012-Int-SP-05
Awareness-2012-Int-IT-08 Awareness-2012-Int-IT-08
Awareness-2012-Int-IT-01 Awareness-2012-Int-IT-01
Awareness-2012-Int-IT-02 Awareness-2012-Int-IT-02
Awareness-2012-Int-IT-04 Awareness-2012-Int-IT-04
Awareness-2012-Int-IT-06 Awareness-2012-Int-IT-06
Awareness-2012-Int-IT-05 Awareness-2012-Int-IT-05
Awareness-2012-Int-IT-09 Awareness-2012-Int-IT-09
Awareness-2012-Int-IT-07 Awareness-2012-Int-IT-07
Awareness-2012-Int-IT-03 Awareness-2012-Int-IT-03
Awareness-2012-Int-DE-07 Awareness-2012-Int-DE-07
Awareness-2012-Int-DE-09 Awareness-2012-Int-DE-09
Awareness-2012-Int-DE-08 Awareness-2012-Int-DE-08
Awareness-2012-Int-FR-08 Awareness-2012-Int-FR-08
Awareness-2012-Int-DE-03 Awareness-2012-Int-DE-03
Awareness-2012-Int-DE-04 Awareness-2012-Int-DE-04
Awareness-2012-Int-DE-05 Awareness-2012-Int-DE-05
Awareness-2012-Int-DE-01 Awareness-2012-Int-DE-01
Awareness-2012-Int-DE-02 Awareness-2012-Int-DE-02
Awareness-2012-Int-FR-03 Awareness-2012-Int-FR-03
Awareness-2012-Int-FR-01 Awareness-2012-Int-FR-01
Awareness-2012-Int-FR-09 Awareness-2012-Int-FR-09
Awareness-2012-Int-FR-05 Awareness-2012-Int-FR-05
Awareness-2012-Int-FR-04 Awareness-2012-Int-FR-04
Awareness-2012-Int-FR-02 Awareness-2012-Int-FR-02
Awareness-2012-Int-FR-07 Awareness-2012-Int-FR-07
Awareness-2012-Int-FR-06 Awareness-2012-Int-FR-06
Awareness-2012-Int-Eng-06 Awareness-2012-Int-Eng-06
Awareness-2012-Int-Eng-08 Awareness-2012-Int-Eng-08
Awareness-2012-Int-Eng-03 Awareness-2012-Int-Eng-03
Awareness-2012-Int-Eng-05 Awareness-2012-Int-Eng-05
Awareness-2012-Int-Eng-04 Awareness-2012-Int-Eng-04
Awareness-2012-Int-Eng-07 Awareness-2012-Int-Eng-07
Awareness-2012-Int-Eng-09 Awareness-2012-Int-Eng-09
Awareness-2012-Int-Eng-02 Awareness-2012-Int-Eng-02
Awareness-2012-Int-Eng-01 Awareness-2012-Int-Eng-01
Awareness-2012-Denver-02 Awareness-2012-Denver-02
Awareness-2012-Denver-01 Awareness-2012-Denver-01
Awareness-2012-Denver-03 Awareness-2012-Denver-03
Awareness-2012-Denver-04 Awareness-2012-Denver-04
nottingham_10_booth nottingham_10_booth
nottingham_08_parfrey nottingham_08_parfrey
nottingham_05_tamhane nottingham_05_tamhane
nottingham_03_jenkins nottingham_03_jenkins
nottingham_04_burge nottingham_04_burge
nottingham_02_hope-gill nottingham_02_hope-gill
nottingham_01_kervitsky nottingham_01_kervitsky
nottingham_11_bray nottingham_11_bray
nottingham_07_gibbons nottingham_07_gibbons
nottingham_09_wheeler nottingham_09_wheeler
nottingham_13_chaudhuri nottingham_13_chaudhuri
nottingham_12_saini nottingham_12_saini
nottingham_06_duck nottingham_06_duck
0915_Beall FRI-patients 0915_Beall FRI-patients
1330_Klein SAT-patients-HD 720p 1330_Klein SAT-patients-HD 720p
0815_Beall FRI-professional 0815_Beall FRI-professional
1630_Oriordan FRI-professional 1630_Oriordan FRI-professional
1500 Immuneworks-professional 1500 Immuneworks-professional
1500 Fibrogen-professional 1500 Fibrogen-professional
1500 Biogen-professional 1500 Biogen-professional
1355_Rosas FRI-professional 1355_Rosas FRI-professional
1015_Lederer SAT-professional 1015_Lederer SAT-professional
1500 Gilead-professional 1500 Gilead-professional
1500 Intermune-professional 1500 Intermune-professional
1415_Ryerson SAT-professional 1415_Ryerson SAT-professional
1435_Brown SAT-professional 1435_Brown SAT-professional
1115_Lee SAT-professional 1115_Lee SAT-professional
0915_Martinez SAT-professional 0915_Martinez SAT-professional
1400_Conosceti SAT-professional 1400_Conosceti SAT-professional
0930_Borok FRI-professional 0930_Borok FRI-professional
1500 Promedior-professional 1500 Promedior-professional
1045_Kawut SAT-professional 1045_Kawut SAT-professional
1330_Noth FRI-professional 1330_Noth FRI-professional
1600_Sheppard FRI-professional 1600_Sheppard FRI-professional
1625_Baird-professional 1625_Baird-professional
1500 BMS-professional 1500 BMS-professional
1305_Garcia FRI-professional 1305_Garcia FRI-professional
1545_Montgomery FRI-professional 1545_Montgomery FRI-professional
1445_Talbert FRI-professional 1445_Talbert FRI-professional
1030_Henke FRI-professional 1030_Henke FRI-professional
0900_Sime FRI-professional 0900_Sime FRI-professional
0800_Rose FRI-professional 0800_Rose FRI-professional
1500 Genentech-professional 1500 Genentech-professional
0845_Cosgrove FRI-professional 0845_Cosgrove FRI-professional
1500 Celgene-professional 1500 Celgene-professional
1330_Swigris SAT-professional 1330_Swigris SAT-professional
1100_Warburton FRI-professional 1100_Warburton FRI-professional
1425_Vancheri SAT-professional 1425_Vancheri SAT-professional
1215_Crowley FRI-patients 1215_Crowley FRI-patients
0915_Herzog SAT-patients 0915_Herzog SAT-patients
1115_Kawut FRI-patients 1115_Kawut FRI-patients
1045_Meehan FRI-patients 1045_Meehan FRI-patients
1115_Jacobs SAT-patients 1115_Jacobs SAT-patients
0900_Rose FRI-patients 0900_Rose FRI-patients
1145_Baird SAT-patients 1145_Baird SAT-patients
1045_Kawut SAT-patients 1045_Kawut SAT-patients
1300_Rose FRI-patients 1300_Rose FRI-patients
0945_Collard FRI-patients 0945_Collard FRI-patients
1300_Sullivan SAT-patients 1300_Sullivan SAT-patients
1045_Bourne SAT-patients 1045_Bourne SAT-patients
0945_Bush SAT-patients 0945_Bush SAT-patients
cosgrove-OHS cosgrove-OHS
fernandez-OHS fernandez-OHS
PFF Care Center Network and PFF Patient Registry PFF Care Center Network and PFF Patient Registry
NewsWatch IPF Segment Featuring Dr. Erica Herzog and Patient NewsWatch IPF Segment Featuring Dr. Erica Herzog and Patient
IPF Summit 2011: From Bench to Bedside Highlights IPF Summit 2011: From Bench to Bedside Highlights
Navigating Medicare and Health Insurance - Miranda G. James, Esq Navigating Medicare and Health Insurance - Miranda G. James, Esq
How to Establish a Support Group and the Benefits of Participation - Wendi R. Mason, MSN, ACNP-BC How to Establish a Support Group and the Benefits of Participation - Wendi R. Mason, MSN, ACNP-BC
What are the Symptoms of Pulmonary Fibrosis and What are the Treatment Options? - Susan S. Jacobs, RN, MS What are the Symptoms of Pulmonary Fibrosis and What are the Treatment Options? - Susan S. Jacobs, RN, MS
Lung Transplantation - Kenneth R. McCurry, MD Lung Transplantation - Kenneth R. McCurry, MD
What is Pulmonary Fibrosis and What are the Causes? - Gregory P. Cosgrove, MD What is Pulmonary Fibrosis and What are the Causes? - Gregory P. Cosgrove, MD
Familial Pulmonary Fibrosis and Genetic Counseling for Pulmonary Fibrosis - Janet Talbert, MS, CGC Familial Pulmonary Fibrosis and Genetic Counseling for Pulmonary Fibrosis - Janet Talbert, MS, CGC
The What, Why, and How of Clinical Trials - Gail G. Weinmann, MD The What, Why, and How of Clinical Trials - Gail G. Weinmann, MD
Pulmonary Rehabilitation for Pulmonary Fibrosis - Brenda Crowe, CRT Pulmonary Rehabilitation for Pulmonary Fibrosis - Brenda Crowe, CRT
Advocacy - Former US Representative Brian Baird, MS, PhD and Mark Shreve Advocacy - Former US Representative Brian Baird, MS, PhD and Mark Shreve
Living with Pulmonary Fibrosis and How to Improve Quality of Life - Kathleen Lindell, PhD, RN Living with Pulmonary Fibrosis and How to Improve Quality of Life - Kathleen Lindell, PhD, RN
Palliative and Hospice Care for Pulmonary Fibrosis Patients - Bronwyn Long, DNP, MBA, RN Palliative and Hospice Care for Pulmonary Fibrosis Patients - Bronwyn Long, DNP, MBA, RN
A Stressful Environment Leading to Epithelial Injury - Timothy S. Blackwell, MD A Stressful Environment Leading to Epithelial Injury - Timothy S. Blackwell, MD
Fibroblasts and Extracellular Matrix: Too Much of a Good Thing? - Eric S. White, MD Fibroblasts and Extracellular Matrix: Too Much of a Good Thing? - Eric S. White, MD
IPF – What’s Age Got to Do With It? - Joseph Lasky, MD IPF – What’s Age Got to Do With It? - Joseph Lasky, MD
Mediators of the Fibroproliferative Injury−Interactions Between the Epithelium and Fibroblast - Andrew M. Tager, MD Mediators of the Fibroproliferative Injury−Interactions Between the Epithelium and Fibroblast - Andrew M. Tager, MD
Defining the Challenges – What Biomarkers Do We Need? - Imre Noth, MD Defining the Challenges – What Biomarkers Do We Need? - Imre Noth, MD
From Bench to Bedside: An Investigator’s Personal Perspective on Taking a Basic Finding to the Real World of Patient Management - Kenneth B. Adler, PhD From Bench to Bedside: An Investigator’s Personal Perspective on Taking a Basic Finding to the Real World of Patient Management - Kenneth B. Adler, PhD
Blood Based Biomarkers to Diagnose and Predict Outcome of IPF - Naftali Kaminski, MD Blood Based Biomarkers to Diagnose and Predict Outcome of IPF - Naftali Kaminski, MD
Genetics and Biomarkers Roundtable Genetics and Biomarkers Roundtable
Update on Transplantation: Update on ECMO - Charles Hoopes, MD Update on Transplantation: Update on ECMO - Charles Hoopes, MD
IPF Summit 2011: Welcome from Daniel M. Rose, MD and Gregory P. Cosgrove, MD IPF Summit 2011: Welcome from Daniel M. Rose, MD and Gregory P. Cosgrove, MD
Saturday Question and Answer Session Saturday Question and Answer Session
Update on Transplantation: Ex-Vivo Perfusion - Robert B. Love, MD Update on Transplantation: Ex-Vivo Perfusion - Robert B. Love, MD
Update on Transplantation: Recent Trends and Results - Kenneth R. McCurry, MD Update on Transplantation: Recent Trends and Results - Kenneth R. McCurry, MD
Treatment of Acute Rejections and BOS - Timothy P. Whelan, MD Treatment of Acute Rejections and BOS - Timothy P. Whelan, MD
Beyond Rales: Are We Really There Yet? - Christine Kim Garcia, MD, PhD Beyond Rales: Are We Really There Yet? - Christine Kim Garcia, MD, PhD
Drug Development in IPF: From the Bedside to Approval - Marianne Mann, MD Drug Development in IPF: From the Bedside to Approval - Marianne Mann, MD
Pulmonary Hypertension - David A. Zisman, MD, MS Pulmonary Hypertension - David A. Zisman, MD, MS
Drug Development in IPF: Lessons Learned in Phase 3 Clinical Trials - A. Bruce Montgomery, MD Drug Development in IPF: Lessons Learned in Phase 3 Clinical Trials - A. Bruce Montgomery, MD
Connective Tissue Fibrotic Disorders - Aryeh Fischer, MD Connective Tissue Fibrotic Disorders - Aryeh Fischer, MD
Lung Injury and Repair Roundtable Lung Injury and Repair Roundtable
Biomarkers for Disease Activity: Designing Drug Studies and Managing Patients - Fernando J. Martinez, MD, MS Biomarkers for Disease Activity: Designing Drug Studies and Managing Patients - Fernando J. Martinez, MD, MS
The Genetic Basis of IPF - David A. Schwartz, MD The Genetic Basis of IPF - David A. Schwartz, MD
Treatment Options Treatment Options
Case Presentations with Master Clinicians Case Presentations with Master Clinicians
Drug Development in IPF: Roundtable Discussion Drug Development in IPF: Roundtable Discussion
Idiopathic Pulmonary Fibrosis: Establishing a Confident Diagnosis - Kevin R. Flaherty, MD, MS Idiopathic Pulmonary Fibrosis: Establishing a Confident Diagnosis - Kevin R. Flaherty, MD, MS
leanne interview leanne interview
The Facts About Lung Transplantation - David Weill, MD The Facts About Lung Transplantation - David Weill, MD
Research and Development in Pulmonary Fibrosis: The Future is Bright - Glenn Rosen, MD Research and Development in Pulmonary Fibrosis: The Future is Bright - Glenn Rosen, MD
Panel Q and A - Full Faculty, Maya Juarez Moderator Panel Q and A - Full Faculty, Maya Juarez Moderator
Managing Advanced Disease: What are the Options? - Janice Noort, RN, MS, NP Managing Advanced Disease: What are the Options? - Janice Noort, RN, MS, NP
Navigating the Why How and When of Oxygen Therapy - Sally McLaughlin, RN, MSN Navigating the Why How and When of Oxygen Therapy - Sally McLaughlin, RN, MSN
Managing Symptoms and Improving Function in Pulmonary Fibrosis - Susan Jacobs, RN, MS Managing Symptoms and Improving Function in Pulmonary Fibrosis - Susan Jacobs, RN, MS
Management Strategies: State of the Art - Harold Collard, MD Management Strategies: State of the Art - Harold Collard, MD
Diagnosis 101: How We Approach Patients with Pulmonary Fibrosis - Andrew Chan, MD Diagnosis 101: How We Approach Patients with Pulmonary Fibrosis - Andrew Chan, MD